Literature DB >> 10725813

Matrix metalloproteinases and venous leg ulceration.

Y Herouy1, D Trefzer, U Zimpfer, E Schöpf, W Wanscheidt, J Norgauer.   

Abstract

Metalloproteinase-mediated proteolysis plays an important role during the phase of venous ulcer formation and wound repair. Venous ulcers manifest as a breakdown of the collagenous stromal tissue and are highly associated to chronic venous insufficiency. A major change in our understanding of the pathogenesis of venous ulcers occurred with the demonstration of extracellular matrix-degrading activity of matrix metalloproteinases to generate a dermal-epidermal skin defect. These proteases were intensely investigated in preceding stages and during wound repair of venous ulcerations. Different studies have revealed their significance in the process of proteolytic remodeling and recognized their potential importance in finding therapeutic rationales to manage late complications of chronic venous ulcers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10725813

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  9 in total

1.  Ovine forestomach matrix biomaterial is a broad spectrum inhibitor of matrix metalloproteinases and neutrophil elastase.

Authors:  Leonardo Negron; Stan Lun; Barnaby C H May
Journal:  Int Wound J       Date:  2012-11-01       Impact factor: 3.315

2.  Cost-effectiveness of treating vascular leg ulcers with UrgoStart(®) and UrgoCell(®) Contact.

Authors:  Matthias Augustin; Katharina Herberger; Knut Kroeger; Karl C Muenter; Lisa Goepel; Reinhard Rychlik
Journal:  Int Wound J       Date:  2014-02-21       Impact factor: 3.315

3.  Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds.

Authors:  Markus Streit; Zsuzsanna Beleznay; Lasse R Braathen
Journal:  Int Wound J       Date:  2006-09       Impact factor: 3.315

4.  Prevention of progressive joint destruction in collagen-induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR255031.

Authors:  Takeshi Ishikawa; Fusako Nishigaki; Susumu Miyata; Yoshitaka Hirayama; Kyoko Minoura; Junko Imanishi; Masahiro Neya; Tsuyoshi Mizutani; Yoshimasa Imamura; Yoichi Naritomi; Hidetsugu Murai; Yoshitaka Ohkubo; Akira Kagayama; Seitaro Mutoh
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

5.  Induction of MMP-1, MMP-3 and TIMP-1 in normal dermal fibroblasts by chronic venous leg ulcer wound fluid*.

Authors:  Kavitha Subramaniam; Cheryl M Pech; Michael C Stacey; Hilary J Wallace
Journal:  Int Wound J       Date:  2008-03       Impact factor: 3.315

6.  Evaluation of the nano-oligosaccharide factor lipido-colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial.

Authors:  Jean-Luc Schmutz; Sylvie Meaume; Ségolène Fays; Zohva Ourabah; Bernard Guillot; Valéne Thirion; Mark Collier; Simon Barrett; J Smith; Serge Bohbot; Anne Dompmartin
Journal:  Int Wound J       Date:  2008-06       Impact factor: 3.315

Review 7.  Protease activity as a prognostic factor for wound healing in venous leg ulcers.

Authors:  Maggie J Westby; Jo C Dumville; Nikki Stubbs; Gill Norman; Jason Kf Wong; Nicky Cullum; Richard D Riley
Journal:  Cochrane Database Syst Rev       Date:  2018-09-01

Review 8.  Amelogenin, an extracellular matrix protein, in the treatment of venous leg ulcers and other hard-to-heal wounds: experimental and clinical evidence.

Authors:  Marco Romanelli; Valentina Dini; Peter Vowden; Magnus S Agren
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

9.  Collagenase-3 (MMP-13) deficiency protects C57BL/6 mice from antibody-induced arthritis.

Authors:  Anjana Singh; Narendiran Rajasekaran; Bettina Hartenstein; Sibylle Szabowski; Mieczyslaw Gajda; Peter Angel; Rolf Bräuer; Harald Illges
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.